# Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

> **NCT04061512** · PHASE2,PHASE3 · RECRUITING · sponsor: **University College, London** · enrollment: 148 (estimated)

## Conditions studied

- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Dexamethasone, cyclophosphamide, rituximab
- **DRUG:** Rituximab, ibrutinib

## Key facts

- **NCT ID:** NCT04061512
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-02-03
- **Primary completion:** 2030-03
- **Final completion:** 2030-03
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2024-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04061512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04061512, "Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04061512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*